Who, when, and how to reverse non-vitamin K oral anticoagulants (Q38655960)

5 September 2017

title

Who, when, and how to reverse non-vitamin K oral anticoagulants (English)

1 reference

5 September 2017

0 references

1 reference

Konstantinos N. Aronis

series ordinal

1 reference

5 September 2017

Elaine M Hylek

1 reference

5 September 2017

publication date

1 December 2015

1 reference

Journal of Thrombosis and Thrombolysis

5 September 2017

published in

1 reference

5 September 2017

1 reference

5 September 2017

1 reference

5 September 2017

page(s)

253-272

1 reference

Dabigatran versus warfarin in patients with atrial fibrillation

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Apixaban versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Edoxaban versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Dabigatran versus warfarin in patients with mechanical heart valves

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Rivaroxaban for thromboprophylaxis in acutely ill medical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Dabigatran versus warfarin in the treatment of acute venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Extended use of dabigatran, warfarin, or placebo in venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Oral rivaroxaban for symptomatic venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Oral apixaban for the treatment of acute venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

The pharmacology of novel oral anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Dynamics of vitamin K antagonist and new oral anticoagulants use in atrial fibrillation: a Danish drug utilization study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Emergency reversal of anticoagulation after intracerebral hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Reversal of coagulopathy using prothrombin complex concentrates is associated with improved outcome compared to fresh frozen plasma in warfarin-associated intracranial hemorrhage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Reversal of dabigatran effects in models of thrombin generation and hemostasis by factor VIIa and prothrombin complex concentrate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

The use of FEIBA® in the correction of coagulation abnormalities induced by dabigatran

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Coagulation Factor Concentrates Fail to Restore Alterations in Fibrin Formation Caused by Rivaroxaban or Dabigatran in Studies With Flowing Blood From Treated Healthy Volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Thrombotic safety of prothrombin complex concentrate (Beriplex P/N) for dabigatran reversal in a rabbit model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Correlation of coagulation markers and 4F-PCC-mediated reversal of rivaroxaban in a rabbit model of acute bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

A specific antidote for dabigatran: functional and structural characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Idarucizumab for Dabigatran Reversal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Safe use of hemodialysis for dabigatran removal before cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Management of dabigatran-induced bleeding with continuous venovenous hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Positive outcome after intentional overdose of dabigatran

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Accidental Rivaroxaban Overdose in a Patient with Pulmonary Embolism: Some Lessons for Managing New Oral Anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

γT -S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-015-1297-0

Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists

21 January 2018

1 reference

12 December 2020

Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.

1 reference

12 December 2020

Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants

1 reference

12 December 2020

Ex vivo reversal of the anticoagulant effects of edoxaban

1 reference

12 December 2020

Dabigatran and its reversal with recombinant factor VIIa and prothrombin complex concentrate: a Sonoclot in vitro study

1 reference

12 December 2020

Effective reversal of edoxaban-associated bleeding with four-factor prothrombin complex concentrate in a rabbit model of acute hemorrhage

1 reference

12 December 2020

Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation

1 reference

12 December 2020

Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro

1 reference

12 December 2020

Reversal of Rivaroxaban-Induced Alterations on Hemostasis by Different Coagulation Factor Concentrates

1 reference

12 December 2020

Use of PER977 to reverse the anticoagulant effect of edoxaban

1 reference

12 December 2020

Idarucizumab Improves Outcome in Murine Brain Hemorrhage Related to Dabigatran

1 reference

12 December 2020

Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model

1 reference

12 December 2020

More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate

1 reference

12 December 2020

Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects

1 reference

12 December 2020

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers

1 reference

12 December 2020

Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers

1 reference

12 December 2020

Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography

1 reference

12 December 2020

Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents

1 reference

12 December 2020

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

1 reference

12 December 2020

10.1007/S11239-015-1297-0

Identifiers

DOI

1 reference

5 September 2017

1 reference